Senior Director Program and Alliance Manager

Take the next step in your career as a Senior Director Project & Alliance Management at Calliditas, a global leader in IgA nephropathy treatment. In the role you will lead their drug projects on a global level and act as Alliance Manager for in-licensed and out-licensed programs.

Calliditas Therapeutics was acquired by Asahi Kasei Corporation in 2024, and you will be joining at an exciting and eventful time, playing a crucial role in the integration process.

Tasks and responsibilities

As Senior Director Project & Alliance Management, you will:

Project Strategy & Leadership

• Define and lead the integrated project plan, ensuring alignment with product vision, development strategy, and corporate objectives
• Drive long-term project direction, including milestone planning, scenario analysis, and critical decision points
• Evaluate key risks and opportunities — scientific, clinical, regulatory, and commercial — to inform portfolio-level prioritization and investment strategies

Project Execution & Risk Management

• Oversee day-to-day project execution across all functions — from preclinical development to regulatory submission and commercialization — ensuring progress against strategic and operational goals
• Manage the critical path and key deliverables, proactively identifying bottlenecks and enabling timely resolution through data-driven risk assessments and mitigation strategies
• Maintain a living risk management framework, with clearly defined risk triggers, ownership, resource implications, and pre-planned contingency actions
• Monitor project health metrics, including timelines, budget adherence, and FTE/resource utilization, and drive corrective actions to ensure delivery remains on track
• Ensure transparent, consistent communication across internal and external stakeholders through regular cross-functional meetings, governance forums and executive reporting

Alliance Management

• Serve as Alliance Manager for partnered programs, ensuring collaborative success and mutual value creation
• Establish and manage joint governance structures, oversee compliance with contractual obligations, and enable transparent, aligned decision-making
• Cultivate trust-based relationships with partner organizations, resolving issues constructively and proactively
  

Additional Responsibilities

• Act as a senior leader in selected corporate strategic initiatives 
• Support out licensing efforts and contricute to the evaluation of new in licensing opportunities

Education, Qualifications and Experience

• Advanced degree (BA/BS/MS/PhD) in Life Sciences, Technical or Scientific discipline
• Several years of pharmaceutical industry experience, with proven leadership of global multidisciplinary drug-development projects — preferably including smaller pharma environments
• Deep expertise in project management methodologies applied to drug development (time, cost, quality and risk)
• Comprehensive knowledge of all drug development phases, functions, and processes
• Demonstrated track record in alliance management with external R&D or commercial partners
• Fluent in English (oral and written)
• Exceptional organizational, decision-making, and communication skills
• Proven ability to motivate teams, drive results, and meet strategic objectives

Start: Upon agreement

Location: World Trade Center, Stockholm 
Salary: Upon agreement

We review applications on an ongoing basis, so do not wait – submit your application today! If you have any questions, feel free to reach out to our recruitment consultant, Camilla Witedal, at .

About Calliditas Therapeutics

Calliditas Therapeutics is a commercial stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2024, Calliditas Therapeutics was acquired by Asahi Kasei corporation and the integration is ongoing with an exciting future and expanded pipeline ahead.

Calliditas’ lead product, developed under the name Nefecon, has received full approval by the FDA and is commercialized in the US under the trade name TARPEYO^®. The product is also after the approval by the European Commission and MHRA commercialized by our partner STADA under the trade name KINPEYGO^®. TARPEYO/KINPEYGO^® is the first treatment approved for IgA nephropathy by the FDA and EMA, respectively. Nefecon recently received full approval in China and is commercialized in China and some other territories under the name Nefecon^® by our partner Everest Medicines.

Calliditas is also evaluating setanaxib in clinical studies to address a variety of diseases, including primary biliary cholangitis (PBC), idiopathic pulmonary fibrosis (IPF), Alport syndrome and solid tumors.

 Calliditas består av ett kreativt team av forskare, kliniker, och andra ämnesexperter som med medkänsla engagerar sig för personer med sällsynta sjukdomar som står inför höga medicinska behov. Vår framgång som företag beror på vår förmåga att fungera som ett enat team, och vi är fast beslutna att tillhandahålla en säker, stimulerande och uppmuntrande miljö där varje anställd ges möjlighet att blomstra och bidra till vårt uppdrag.